Dake Benjamin T 4
4 · Aerovate Therapeutics, Inc. · Filed Mar 28, 2024
Insider Transaction Report
Form 4
Dake Benjamin T
See Remarks
Transactions
- Sale
Common Stock
2024-03-27$27.97/sh−11,068$309,519→ 1,291 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-27−11,068→ 29,000 totalExercise: $10.61Exp: 2031-12-13→ Common Stock (11,068 underlying) - Exercise/Conversion
Common Stock
2024-03-27$10.61/sh+11,068$117,431→ 12,359 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.